Research Paper Volume 10, Issue 10 pp 2741—2754
A single-nucleotide polymorphism (rs1805087) in the methionine synthase (METH) gene increases the risk of prostate cancer
- 1 Department of Urology, Nantong Tongzhou District People’s Hospital, Nantong 226300, China
- 2 Department of Orthopedics, Qidong People’s Hospital, Nantong 226200, China
- 3 Department of Clinical Pharmacy, the Affiliated Jiangyin Hospital of Southeast University Medical School, Jiangyin 214400, China
- 4 Department of Orthopedics, the Affiliated Jiangyin Hospital of Southeast University Medical School, Jiangyin 214400, China
received: July 6, 2018 ; accepted: September 26, 2018 ; published: October 18, 2018 ;https://doi.org/10.18632/aging.101584
How to Cite
Copyright: Zhang et al. This is an open‐access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Methionine synthase (METH, i.e., MTR) is a key enzyme in the folate pathway, which plays a critical role in the synthesis, repair, and methylation of DNA. The association between METH gene polymorphisms and prostate cancer susceptibility remains ambiguous. Thus, we performed an updated meta-analysis of METH single-nucleotide polymorphism rs1805087 involving 12 independent case-control studies comprising 9986 prostate cancer patients and 40134 controls. The odds ratio and 95% confidence intervals were applied to evaluate the relation of this single-nucleotide polymorphism with prostate cancer. Statistical analysis was performed in STATA 11.0. A significant association was found between rs1805087 and increased prostate cancer risk, overall and with Hardy–Weinberg equilibrium. In subgroup analyses (based on ethnicity, source of control, genotyping methods, or publication status), similar associations were observed (e.g., genotype GA vs. AA: odds ratio 1.19, 95% confidence interval 1.01–1.40 among whites; G allele vs. A allele: odds ratio 1.14, 95% confidence interval 1.02–1.28 among hospital-based controls). Thus, the common polymorphism (rs1805087) of METH may be associated with increased prostate cancer risk. Further studies with a larger sample size and detailed gene–environment interactions should be conducted to identify the role of METH polymorphisms in prostate cancer susceptibility.